Navigation Links
Non-Hormonal Male Contraceptive Based on Sperm Block Underway

A novel, non-hormonal male contraceptive device that targets sperms, called Intra Vas Device (IVD) has been approved by the FDA for a study// involving 90 men. Men and women have long been promised a male version of the female contraceptive pill. However, this first male contraceptive to be marketed market may not be hormonal at all.

The study, to take place in Seattle, Washington and St. Paul, Minnesota, will bring men one-step closer to having their first new contraceptive in more than a century.

‘Preliminary studies in animals and men show that this doesn't have the side effects of hormonal methods,’ said Jim Stice, president of Shepherd Medical Company, a consortium of researchers and entrepreneurs developing the device. ‘The concept is pretty simple: A set of tiny plugs block sperm as they travel through a tube called the vas deferens. Men don't need to worry that they'll have acne or gain weight or have their sex drive go up or down--all things that can happen when you manipulate hormones.’

This will be the second contraceptive study of the IVD in men. In the pilot study, the method was very effective: All 30 men either had no sperm in their semen or had levels too low to cause a pregnancy. Early monkey studies showed reversibility after seven months of use, but reversibility studies in men have thus far only tested same-day insertion and removal.

Elaine Lissner, director of the nonprofit Male Contraception Information Project, is cautiously optimistic. ‘The Holy Grail of contraception is a long-term, reversible method without any hormonal side effects,’ she said. ‘Right now the IVD developers can't guarantee that it's reversible in men like it has been in animals, so they're billing it as a kinder, gentler vasectomy. But if it turns out to be reversible, they're going to have a line out the door.’

The concept of blocking sperm in the vas deferens is not new: each year about 500,000 American men get v asectomies, a simple 15-minute procedure in which the vas deferens is cut and its ends closed off. About one in six American men over 35 already has a vasectomy. However, vasectomy is generally considered permanent, leaving younger men with condoms as their only option.

Men in long-term relationships, such as Jacob Kostecka, 29, are likely to be the first ones interested in the IVD. ‘My wife doesn't want to take hormonal methods, and I don't blame her. I wouldn't want to take that stuff and have it mess with my body either! But most other methods are clumsy and ruin the moments of intimacy we have together. Something like this could be really appealing.’

The news about the IVD comes on the heels of the announcement that RISUG, a vas deferens-based male contraceptive developed in India, will resume trials in men. RISUG has been shown reversible in animals. Researchers in China are also having success with a new vas deferens device, though theirs is not being billed as reversible.

Kirsten Thompson, director of the Male Contraceptive Coalition, stresses that men can help speed development of these methods. ‘Men clearly want to know about these options--our website gets thousands of visitors each week. But there are still questions to be answered about the IVD's reversibility,’ she said. She added that ‘Men who don't want any more children and live near a study site can help answer those questions by volunteering. Otherwise, the best thing they can do is spread the word.’

Source Eurekalert
'"/>




Related medicine news :

1. Contraceptives via Internet
2. FDA Approves Contraceptive Ring
3. Contraceptives decreases Libido
4. Contraceptives have dual effects
5. Drugs For Anthrax May Interfere With Oral Contraceptives
6. Contraceptive pill to reduce PMS
7. Smoking and Oral Contraceptives:
8. Contraceptive pills may lead to deformities in babies
9. Low-Dose Oral Contraceptives May Increase Risk For Heart Attack Or Stroke
10. Prevent Multiple Sclerosis From Oral Contraceptives
11. Usage Of Oral Contraceptives Need Not Be Feared By SLE Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... With ... intervention to walk, the demand for a sustainable product to aid in the rehabilitation ... and aid in the recovery of individuals with hemiplegia due to stroke. , Ekso ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response ... many who are unaware of the plight of aphasia. In collaboration with the ... “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively unknown, ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in ... come courtesy of leaders in the nursing and health care industry. It also provides ... associations—namely Abilene Christian University. , As the nursing industry is coming out of ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... 2016 , ... Cabot Corporation, Pfizer, and 3M are responsible ... documents and SEC filings. A jury has returned a verdict of $32.8 ... Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 million in ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... May 27, 2016 Amarantus BioScience Holdings, ... developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced ... presenting at two upcoming investor conferences: SeeThru Equity ... Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, ...
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May ... QGEN ; Frankfurt Prime Standard: QIA) today announced that ... with Therawis Diagnostics GmbH to develop and commercialize predictive assays ... market PITX2 as a marker to predict effectiveness of anthracycline ... "We are pleased to partner with Therawis, which ...
Breaking Medicine Technology: